2025
Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profile
2021
Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh risk
2015
Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis
Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World Journal Of Hepatology 2015, 7: 1797-1806. PMID: 26167253, PMCID: PMC4491909, DOI: 10.4254/wjh.v7.i13.1797.Peer-Reviewed Original ResearchTransjugular intrahepatic portosystemic stent shuntRefractory hepatic hydrothoraxHepatic hydrothoraxSystematic reviewClass C diseaseRandom-effects modelComprehensive literature searchChild-TurcottMost patientsPoor prognosisMean ageMean durationEligible studiesC diseaseMean changePatientsLiterature searchHydrothoraxShuntI testsEMBASEPrognosisReviewEncephalopathyMmHg
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply